Literature DB >> 34039487

Intensive care management of acute-on-chronic liver failure.

William Bernal1, Constantine Karvellas2, Faouzi Saliba3, Fuat H Saner4, Philippe Meersseman5.   

Abstract

The syndrome of acute-on-chronic liver failure combines deterioration of liver function in a patient with chronic liver disease, with the development of extrahepatic organ failure and high short-term mortality. Its successful management demands a rapid and coherent response to the development of dysfunction and failure of multiple organ systems in an intensive care unit setting. This response recognises the features that distinguish it from other critical illness and addresses the complex interplay between the precipitating insult, the many organ systems involved and the disordered physiology of underlying chronic liver disease. An evidence base is building to support the approaches currently adopted and outcomes for patients with this condition are improving, but mortality remains unacceptably high. Herein, we review practical considerations in critical care management, as well as discussing key knowledge gaps and areas of controversy that require further focussed research.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute-on-chronic liver failure; Critical illness; Encephalopathy; Intensive care; Multiple organ failure; Transplantation

Mesh:

Year:  2021        PMID: 34039487     DOI: 10.1016/j.jhep.2020.10.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  2 in total

1.  New concepts and perspectives in decompensated cirrhosis.

Authors:  Rajiv Jalan; Gyongyi Szabo
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

2.  Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP)-a single center, open-label, three-arm, randomized, controlled intervention trial.

Authors:  Asieb Sekandarzad; Enya Weber; Eric Peter Prager; Erika Graf; Dominik Bettinger; Tobias Wengenmayer; Alexander Supady
Journal:  Trials       Date:  2022-03-18       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.